Compare KD & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | VERA |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2021 | 2021 |
| Metric | KD | VERA |
|---|---|---|
| Price | $13.13 | $40.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $31.00 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 3.0M | 1.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.95 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $15,057,000,000.00 | N/A |
| Revenue This Year | $3.96 | N/A |
| Revenue Next Year | $0.41 | $416.83 |
| P/E Ratio | $16.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $18.53 |
| 52 Week High | $43.74 | $56.05 |
| Indicator | KD | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 47.53 |
| Support Level | $12.07 | $37.36 |
| Resistance Level | $13.81 | $42.73 |
| Average True Range (ATR) | 0.51 | 2.14 |
| MACD | 0.31 | 0.06 |
| Stochastic Oscillator | 87.77 | 46.17 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.